纳武利尤单抗用于索拉非尼初治和经治晚期肝细胞癌患者:CheckMate 040 的 5 年随访
CheckMate 040 研究 5 年随访显示,索拉非尼初治和经治晚期肝细胞癌患者接受纳武利尤单抗单药治疗,盲法独立中心评审的客观缓解率分别为 20% 和 14%,中位总生存期分别为 26.6 个月和 15.1 个月,5 年总生存率分别为 14% 和 12%,未发现新的安全性信号。
要点
- 索拉非尼初治组盲法独立中心评审客观缓解率 20%,经治组 14%。
- 索拉非尼初治组中位总生存期 26.6 个月,经治组 15.1 个月。
- 两组 5 年总生存率分别为 14% 和 12%,未发现新的安全性信号。
核心结论
- 经过 5 年随访,纳武利尤单抗单药治疗在索拉非尼初治和经治晚期肝细胞癌患者中持续提供持久的临床获益,安全性可控。
研究设计与样本
- CheckMate 040 研究,报告索拉非尼初治组和索拉非尼经治组患者的 5 年随访结果。
- 患者接受纳武利尤单抗单药治疗,剂量递增阶段为 0.1-10.0 mg/kg,剂量扩展阶段为 3 mg/kg,每 2 周一次,直至疾病进展或不可接受的毒性。
- 索拉非尼初治组 80 例,索拉非尼经治组 154 例接受治疗;两组最短随访时间均为 60 个月。
- 剂量递增阶段主要终点为安全性和耐受性;剂量扩展阶段主要终点为盲法独立中心评审和研究者按 RECIST 版本 1.1 评估的客观缓解率。
主要发现
- 盲法独立中心评审的客观缓解率在索拉非尼初治组为 20%(95%CI 12% 至 30%),在索拉非尼经治组为 14%(95%CI 9% 至 21%)。
- 缓解的发生与肝细胞癌病因或基线肿瘤细胞程序性死亡配体 1(PD-L1)表达水平无关。
- 中位总生存期在索拉非尼初治组为 26.6 个月(95%CI 16.6-30.6 个月),在索拉非尼经治组为 15.1 个月(95%CI 13.0-18.2 个月)。
- 3 年总生存率在索拉非尼初治组为 28%,在索拉非尼经治组为 20%;5 年总生存率分别为 14% 和 12%。
- 未发现新的安全性信号;3/4 级治疗相关不良事件在索拉非尼初治组和经治组的发生率分别为 33% 和 21%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with advanced hepatocellular carcinoma (aHCC) have a poor prognosis and high mortality. Nivolumab monotherapy demonstrated clinical benefit with an acceptable safety profile in patients with aHCC in the CheckMate 040 study. Five-year follow-up of the sorafenib-naive and sorafenib-experienced groups of CheckMate 040 is presented here. PATIENTS AND METHODS: Patients received nivolumab monotherapy at dose levels of 0.1-10.0 mg/kg (dose-escalation phase) or 3 mg/kg (dose-expansion phase) every 2 weeks until disease progression or unacceptable toxicity. Primary endpoints were safety and tolerability (dose escalation), and objective response rate (ORR) by blinded independent central review (BICR) and by investigator as per RECIST version 1.1 (dose expansion). RESULTS: Eighty sorafenib-naive and 154 sorafenib-experienced patients were treated. Minimum follow-up in both groups was 60 months. ORR as per BICR was 20% [95% confidence interval (CI) 12% to 30%] and 14% (95% CI 9% to 21%) in the sorafenib-naive and sorafenib-experienced groups, respectively. Responses occurred regardless of HCC etiology or baseline tumor cell programmed death-ligand 1 (PD-L1) expression levels. Median overall survival (OS) was 26.6 months (95% CI 16.6-30.6 months) and 15.1 months (95% CI 13.0-18.2 months) in sorafenib-naive and sorafenib-experienced patients, respectively. The 3-year OS rates were 28% in the sorafenib-naive and 20% in the sorafenib-experienced groups; 5-year OS rates were 14% and 12%, respectively. No new safety signals were identified; grade 3/4 treatment-related adverse events were observed in 33% and 21% of patients in the sorafenib-naive and sorafenib-experienced groups, respectively. Biomarker analyses showed that baseline PD-L1 expression ≥1% was associated with higher ORR and longer OS compared with PD-L1 <1%. In the sorafenib-naive group, patients with OS ≥3 years exhibited higher baseline CD8 T-cell density compared with those with OS <1 year. CONCLUSION: With 5 years of follow-up, nivolumab monotherapy continued to provide durable clinical benefit with manageable safety in sorafenib-naive and sorafenib-experienced patients with aHCC.
引用
- El-Khoueiry AB, Trojan J, Meyer T, et al. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040. Ann Oncol. 2023. PMID: 38151184. doi:10.1016/j.annonc.2023.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。